Dark

Check out our Level2View

CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
stock NASDAQ

Inactive

Jul 31, 2024

44.96USD+0.739%(+0.33)15,037,313

Pre-market

0.00USD-100.000%(-44.63)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 10, 2022

06:30AM EST Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia GlobeNewswire Inc

Jan 5, 2022

10:45AM EST JP Morgan Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $50 Benzinga

Jan 3, 2022

07:00AM EST Cerevel to Present at the 40th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Dec 16, 2021

07:13AM EST Cerevel Therapeutics And Herophilus Announce Collaboration To Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia Benzinga

07:00AM EST Cerevel Therapeutics and Herophilus Announce Collaboration to GlobeNewswire Inc

06:09AM EST HC Wainwright & Co. Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $50 Benzinga

Nov 10, 2021

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

07:48AM EST Cerevel Therapeutics Filing Shows Registration For ~37.4M Share Common Stock Shelf Offering Via Selling Shareholders Benzinga

06:46AM EST Cerevel Therapeutics Q3 Loss Per Share $0.43 Vs Loss $0.62 Last Year RTTNews

06:40AM EST Cerevel Therapeutics Hldg Q3 EPS $(0.43) Misses $(0.40) Estimate Benzinga

06:30AM EST Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022 GlobeNewswire Inc

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 1, 2021

06:30AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that it will participate in four upcoming virtual investor conferences during the months of November and December. GlobeNewswire Inc

Oct 20, 2021

06:30AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report third quarter 2021 financial results and pipeline updates on Wednesday, November 10, 2021, before the U.S. financial markets open. GlobeNewswire Inc

Oct 7, 2021

07:11AM EDT Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia Benzinga

07:00AM EDT Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in GlobeNewswire Inc

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

05:00PM EDT Cerevel Therapeutics Announces Departure Of CFO Kathy Yi Benzinga

05:00PM EDT Current Chief Accounting Officer Mark Bodenrader named as interim CFO GlobeNewswire Inc

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 10, 2021

07:00AM EDT Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophrenia GlobeNewswire Inc

Sep 8, 2021

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

Sep 7, 2021

08:14AM EDT Morgan Stanley Maintains Overweight on Cerevel Therapeutics Hldg, Raises Price Target to $39 Benzinga

Sep 3, 2021

07:31AM EDT The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself Benzinga

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Sep 1, 2021

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that members of the management team will participate in two upcoming virtual investor conferences during the month of September. GlobeNewswire Inc

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 28, 2021

01:06PM EDT The Past Week's Notable Insider Buys: Callon Petroleum, Cricut, Krispy Kreme And More Benzinga

Aug 26, 2021

05:15AM EDT Cerevel Therapeutics Holdings Director Joseph Edelman Reported Purchase of 175,585 Shares @ Avg Price of $27.53/Share in Form 4 Filing on Wednesday Benzinga

Aug 11, 2021

09:06AM EDT Earnings Scheduled For August 11, 2021 Benzinga

06:34AM EDT Cerevel Therapeutics Hldg Q2 EPS $(0.42) Misses $(0.39) Estimate Benzinga

06:30AM EDT Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia GlobeNewswire Inc

04:27AM EDT Earnings Scheduled For August 11, 2021 Benzinga

Jul 30, 2021

07:00AM EDT Cerevel Therapeutics Announces Redemption of Public Warrants GlobeNewswire Inc

Jul 22, 2021

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report second quarter 2021 financial results and provide a pipeline update on Wednesday, August 11, 2021, before the U.S. financial markets open. GlobeNewswire Inc

Jul 11, 2021

05:10PM EDT The Past Week's Notable Insider Buys Include Krispy Kreme, Biotechs, SPACs And More Benzinga

Jul 2, 2021

07:31AM EDT Cerevel Therapeutics Raises $350M Via Equity Issued At $25/Share Benzinga

05:41AM EDT Cerevel Therapeutics Priced 14M Share Public Offering of Common Stock @$25/Share Benzinga

Jul 1, 2021

09:50PM EDT Cerevel Therapeutics Announces Pricing of $350 Million Public GlobeNewswire Inc

Jun 30, 2021

07:49AM EDT Cerevel Therapeutics Shares Drops After Launching Equity Offering Of 14M Shares Benzinga

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 29, 2021

04:24PM EDT Cerevel Therapeutics Announces Proposed Public Offering of Common GlobeNewswire Inc

04:23PM EDT Cerevel Therapeutics Holdings Files For Offering Of 14M Shares Of Common Stock Benzinga

03:01PM EDT Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge Benzinga

12:18PM EDT Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher Benzinga

11:16AM EDT Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results Benzinga

09:59AM EDT Shares of Cerevel Therapeutics Holdings, Inc. (CERE, CEREW) are surging over 75% on Tuesday morning after the clinical-stage biopharmaceutical company focused on neuroscience diseases announced positive results from an early stage study of Schizophrenia treatment. RTTNews

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

06:34AM EDT Cerevel Therapeutics Announces Topline Results For CVL-231 In Phase 1b Clinical Trial In Patients With Schizophrenia; Says Both Doses Demonstrated Clinically Meaningful And Statistically Significant In PANSS Total Score Benzinga

06:30AM EDT Both doses of CVL-231 demonstrated a clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks and were overall well-tolerated compared with placebo GlobeNewswire Inc

Jun 18, 2021

12:47PM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 18, 2021 Benzinga

10:59AM EDT Cerevel Therapeutics shares were trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and a $27 price target. Benzinga

07:48AM EDT Morgan Stanley Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $27 Benzinga

Jun 15, 2021

07:18AM EDT Cerevel Therapeutics Announces Fast Track Designation Granted By The FDA To CVL-871 For The Treatment Of Dementia-Related Apathy Benzinga

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CVL-871, a D1/D5 partial agonist in development for the treatment of dementia-related apathy. GlobeNewswire Inc

May 27, 2021

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that it will participate in two upcoming virtual investor conferences during the month of June. GlobeNewswire Inc

May 17, 2021

06:35AM EDT Cerevel Therapeutics Q1 EPS $(0.40) Beats $(0.41) Estimate Benzinga

06:30AM EDT Cerevel Therapeutics Reports First Quarter 2021 Financial Results GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 4, 2021

07:00AM EDT Cerevel Therapeutics Announces the Appointment of Scott M. Akamine GlobeNewswire Inc

Apr 29, 2021

07:00AM EDT Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report first quarter 2021 financial results on Monday, May 17, 2021, before the U.S. financial markets open. GlobeNewswire Inc

Apr 21, 2021

07:00AM EDT Cerevel Therapeutics Appoints Abraham N. Ceesay as President GlobeNewswire Inc

Apr 13, 2021

06:42AM EDT Cerevel Therapeutics Announces $125 Mln Non-dilutive Financing Transaction With NovaQuest, Bain Capital For Tavapadon RTTNews

06:33AM EDT Cerevel Therapeutics Announces $125M Financing Transaction With NovaQuest And Bain Capital To Fund Phase 3 Development Program For Tavapadon In Paskinson's Benzinga

06:30AM EDT Risk-sharing arrangement with NovaQuest and Bain Capital will fund the full tavapadon Phase 3 development program for Parkinsons disease through planned NDA submission GlobeNewswire Inc

Mar 24, 2021

06:47AM EDT Cerevel Therapeutics Q4 Net Loss Attributable To Common Stockholders $29.3 Mln Or $0.27 Per Share RTTNews

06:31AM EDT Cerevel Therapeutics Hldg Q4 EPS $(0.27) Beats $(0.45) Estimate Benzinga

06:30AM EDT Data readout of Phase 1b trial of CVL-231 in patients with schizophrenia now expected mid-year 2021 GlobeNewswire Inc

04:29AM EDT Earnings Scheduled For March 24, 2021 Benzinga

Mar 22, 2021

07:00AM EDT Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that Chairperson and Chief Executive Officer, Tony Coles, M.D. will participate in a fireside chat at the Stifel 3rd Annual CNS Day on Wednesday, March 31, 2021 at 9:00 a.m. EDT. GlobeNewswire Inc

Feb 24, 2021

07:00AM EST Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced it will report fourth quarter and full year 2020 financial results on Wednesday, March 24, 2021, before the U.S. financial markets open. GlobeNewswire Inc

Feb 23, 2021

07:00AM EST Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, today announced that the company will participate in the upcoming Cowen 41st Annual Health Care Conference. GlobeNewswire Inc

Jan 28, 2021

07:00AM EST Darigabat now the international nonproprietary name (INN) for CVL-865, a Phase 2 GABA Positive Allosteric Modulator GlobeNewswire Inc

Jan 21, 2021

07:00AM EST Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced today that it has appointed the Honorable Deval Patrick and Deborah Baron to serve as independent members of its Board of Directors. GlobeNewswire Inc

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 14, 2020

07:00AM EST Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs GlobeNewswire Inc

Dec 10, 2020

06:42AM EST Goldman Sachs Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $24 Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

07:23AM EST Cerevel Therapeutics Names Ruth McKernan To Board RTTNews

07:00AM EST Cerevel Therapeutics Announces the Appointment of Dr. Ruth GlobeNewswire Inc

Dec 4, 2020

08:04AM EST The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOs Benzinga

07:00AM EST Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced it will host a live webcast providing a current corporate overview, followed by a moderated question and answer session on Monday, December 14. GlobeNewswire Inc

Dec 2, 2020

07:35AM EST The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod Benzinga

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 23, 2020

11:08AM EST Jefferies Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $18 Benzinga

07:00AM EST Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced Chairperson and Chief Executive Officer Tony Coles, M.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 3:05 p.m. EST. GlobeNewswire Inc

Nov 16, 2020

06:32AM EST Cerevel Therapeutics Hldg Q3 EPS $(4.34) Up From $(5.16) YoY Benzinga

06:30AM EST Participants dosed in clinical trials for lead programs in schizophrenia, epilepsy, anxiety and Parkinsons disease GlobeNewswire Inc

Nov 14, 2020

01:45PM EST Last Week's Notable Insider Buys: Kraft, IBM, Vertex And More Benzinga

Nov 9, 2020

09:38AM EST Benzinga's Top Upgrades, Downgrades For November 9, 2020 Benzinga

06:11AM EST Stifel Initiates Coverage On Cerevel Therapeutics Hldg with Buy Rating, Announces Price Target of $17 Benzinga

Nov 5, 2020

08:38AM EST Cerevel Therapeutics 13D From BC Perception Holdings Shows 47.4% Stake In Co. Benzinga

Nov 4, 2020

07:00AM EST Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain totreatneurosciencediseases, announced that members of the management team will participate in three upcoming virtual investor conferences during the month of November. GlobeNewswire Inc

Oct 30, 2020

07:02AM EDT Cerevel Therapeutics Reports First Patients Dosed In All Phase 3 Trials Of Tavapadon For Treatment Of Parkinson's Disease Benzinga

07:00AM EDT Cerevel Therapeutics Announces First Patients Dosed in all Phase 3 GlobeNewswire Inc

Oct 28, 2020

07:24AM EDT Cerevel Therapeutics Reports Completion Of Business Combo With Arya Sciences Acquisition Corp II; Will Commence Trading On Nasdaq Oct. 28 Under Ticker 'CERE' Benzinga

07:00AM EDT Business combination transaction with Arya Sciences Acquisition Corp II, a special purpose acquisition company sponsored by Perceptive Advisors, completed on October 27, 2020 GlobeNewswire Inc

Share